Growth hormone for in vitro fertilization.

What It Covers

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRH (Growth Hormone-Releasing Hormone) in this systematic review publication.

Most studies investigate the role of GH in normally ovulating infertile women but there is also an interest in the effect of GH on women who respond poorly to ovulation induction and IVF.

The researchers searched the Cochrane Menstrual Disorders and Subfertility Group's trials register (24 March 2003), the Cochrane Central Register of Controlled Trials (Cochrane Library Issue 1, 2003), MEDLINE (1966 to Feb 2003), EMBASE (1988 to Feb 2003) and Biological Abstracts (1969 to Feb 2003).

Who the Included Studies Covered

PubMed tags the participants as women only.

All randomised controlled trials were included if they addressed the research question and provided outcome data for intervention and control subjects.

How the Review Was Done

Validity was assessed in terms of method of randomisation, completeness of follow-up and co-intervention.

What Was Measured

Assessment of trial quality and extraction of relevant data was performed independently by two reviewers.

PubMed files the paper under topics including Fertilization in Vitro, Growth Hormone, Growth Hormone-Releasing Hormone, Ovulation Induction and Randomized Controlled Trials as Topic.

What This Means in Plain Language

This is a systematic review of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRH (Growth Hormone-Releasing Hormone).

Its findings take up roughly 10 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2003 (The Cochrane database of systematic reviews), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page and the GHRH (Growth Hormone-Releasing Hormone) compound page, all human trials.